These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 36082857)

  • 21. Recent Progress in the Pharmacotherapy of Alzheimer's Disease.
    Khoury R; Patel K; Gold J; Hinds S; Grossberg GT
    Drugs Aging; 2017 Nov; 34(11):811-820. PubMed ID: 29116600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefits and risks of add-on therapies for Alzheimer's disease.
    Magierski R; Sobow T
    Neurodegener Dis Manag; 2015 Oct; 5(5):445-62. PubMed ID: 26517312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanistic Insight into the Design of Chemical Tools to Control Multiple Pathogenic Features in Alzheimer's Disease.
    Han J; Du Z; Lim MH
    Acc Chem Res; 2021 Oct; 54(20):3930-3940. PubMed ID: 34606227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disease-modifying drugs in Alzheimer's disease.
    Ghezzi L; Scarpini E; Galimberti D
    Drug Des Devel Ther; 2013 Dec; 7():1471-8. PubMed ID: 24353405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Strategies and Novel Drug Approaches for Alzheimer Disease.
    Ghai R; Nagarajan K; Arora M; Grover P; Ali N; Kapoor G
    CNS Neurol Disord Drug Targets; 2020; 19(9):676-690. PubMed ID: 32679025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carthamus tinctorius L.: A natural neuroprotective source for anti-Alzheimer's disease drugs.
    Liang Y; Wang L
    J Ethnopharmacol; 2022 Nov; 298():115656. PubMed ID: 36041691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential Neuroprotective Strategies using Smart Drug Delivery Systems for Alzheimer's Disease.
    Khan J; Yadav S; Alam MA
    Infect Disord Drug Targets; 2024; 24(3):e231023222565. PubMed ID: 37873911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Donepezil Derivatives Targeting Amyloid-β Cascade in Alzheimer's Disease.
    Mezeiova E; Chalupova K; Nepovimova E; Gorecki L; Prchal L; Malinak D; Kuca K; Soukup O; Korabecny J
    Curr Alzheimer Res; 2019; 16(9):772-800. PubMed ID: 30819078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease.
    Prvulovic D; Schneider B
    Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):1039-50. PubMed ID: 24785550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel Therapeutic Strategies for Dementia.
    Cacabelos R; Torrellas C; Carrera I; Cacabelos P; Corzo L; Fernández-Novoa L; Tellado I; Carril JC; Aliev G
    CNS Neurol Disord Drug Targets; 2016; 15(2):141-241. PubMed ID: 26831267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antidementia Drug Therapy of Alzheimer's Dementia: Status 2018 and Outlook].
    Hausner L; Frölich L
    Dtsch Med Wochenschr; 2019 Feb; 144(3):156-160. PubMed ID: 30703832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miRNAs as Therapeutic Tools in Alzheimer's Disease.
    Lee CY; Ryu IS; Ryu JH; Cho HJ
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies.
    Cummings JL
    Rev Neurol Dis; 2007; 4(2):57-62. PubMed ID: 17609636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New and emerging treatments for Alzheimer's disease.
    Corbett A; Smith J; Ballard C
    Expert Rev Neurother; 2012 May; 12(5):535-43. PubMed ID: 22550982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholinesterase inhibitors and non-steroidal anti-inflammatory drugs as Alzheimer's disease therapies: an updated umbrella review of systematic reviews and meta-analyses.
    Wang CH; Wang LS; Zhu N
    Eur Rev Med Pharmacol Sci; 2016 Nov; 20(22):4801-4817. PubMed ID: 27906438
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.